Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Jun 19, 2019 - There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Jun 18, 2019 - Top Analyst Reports for Broadcom, Amgen & NVIDIA
Jun 18, 2019 - Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Jun 18, 2019 - Pfizer could be only the first of several to spend billions buying smaller biotech.
Jun 16, 2019 - When your time frame is decades, you need to look differently at an investment. Here are three that can stand the test of time.
Jun 14, 2019 - FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.
Jun 13, 2019 - Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
Jun 12, 2019 - Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.